Tyrosine kinase inhibitor neratinib attenuates liver fibrosis by targeting activated hepatic stellate cells

Liver fibrosis, a common outcome of chronic liver disease characterized by excessive accumulation of extracellular matrix (ECM), is a leading cause of mortality worldwide. The tyrosine kinase inhibitor neratinib is a human epidermal growth factor receptor 2 (HER2) inhibitor approved by the FDA for H...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yong Joo, An, Hyoung-Tae, Park, Jong-Sung, Park, Ogyi, Duh, Alexander J., Kim, Kwangmeyung, Chung, Kyu Hyuck, Lee, Kang Choon, Oh, Yumin, Lee, Seulki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479613/
https://www.ncbi.nlm.nih.gov/pubmed/32901093
http://dx.doi.org/10.1038/s41598-020-71688-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479613/
https://www.ncbi.nlm.nih.gov/pubmed/32901093
http://dx.doi.org/10.1038/s41598-020-71688-2

Ejemplares similares